None listed
Conditions
Brief summary
Patients of End Stage renal disease on maintenance haemodialysis will be divided into two groups. The test group will be given levocarnitine injection after each session of haemodialysis while the control group will be given placebo. Patients' wellness as per SF 36 questionnaire will be compared before and after levocarnitine treatment for two months.
Interventions
Levocarnitine 1 gram (diluted to 20ml with normal saline) will be administered into the venous port of dialysis circuit/ tubing, slowly over 3- 5 minutes within the first 15 minutes of starting each haemodialysis session. This would be done by the dialysis technician responsible for patient care during that particular haemodialysis session.
Levocarnitine would be administered two times each week for a total of 2 months
Sponsors
Dr. Obaid Ur Rehman, Pak Emirates Military Hospital Rawalpindi Pakistan
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(1) Patients diagnosed with end-stage renal disease undergoing maintenance haemodialysis two times a week for at least 3 months. (2) Patients willing to participate and provide informed consent.
Exclusion criteria
(1) Patients with a history of allergic reactions to levocarnitine. (2) Patients who have received L-carnitine therapy in previous 3 months. (3) Patients with cognitive difficulties who are unable to comprehend questions on the SF-36 questionnaire (4) Limited mobility
Outcome results
None listed